Immunocore/$IMCR
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Primary listing
Employees
524
Headquarters
Website
Immunocore Metrics
BasicAdvanced
$1.5bn
-
-$0.55
0.74
-
Price and volume
Market cap
$1.5bn
Beta
0.74
52-week high
$40.71
52-week low
$27.56
Average daily volume
351k
Financial strength
Current ratio
4.181
Quick ratio
3.856
Long term debt to equity
110.164
Total debt to equity
110.671
Interest coverage (TTM)
-1.21%
Profitability
EBITDA (TTM)
-11.369
Gross margin (TTM)
32.28%
Net profit margin (TTM)
-6.68%
Operating margin (TTM)
-3.57%
Effective tax rate (TTM)
-131.41%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
-0.88%
Return on equity (TTM)
-7.14%
Valuation
Price to revenue (TTM)
3.599
Price to book
3.8
Price to tangible book (TTM)
3.8
Price to free cash flow (TTM)
-48.319
Free cash flow yield (TTM)
-2.07%
Free cash flow per share (TTM)
-0.609
Growth
Revenue change (TTM)
23.75%
Earnings per share change (TTM)
26.27%
3-year revenue growth (CAGR)
27.07%
3-year earnings per share growth (CAGR)
-21.12%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs